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Introduction
Human Immunodeficiency Virus (HIV)/
Acquired immunodeficiency syndrome (AIDS) remains 
a global problem to date [1]. With the development of 
effective ARV therapy (ART), HIV/AIDS had evolved 
into a chronic illness [2]. The morbidity and mortality 
of HIV/AIDS patients are often associated with 
coinfections. One of the most common coinfections 
in HIV/AIDS patients is pulmonary tuberculosis (TB). 
Problems related to abnormal coagulation had also 
been reported in HIV/AIDS patients [1]. The acute 
inflammation process experienced by HIV patients may 
trigger abnormalities in the coagulation process due 
to stimulation of the extrinsic rather than the intrinsic 
pathway. Endothelial dysfunction in HIV/AIDS infection, 
leading to the activation and consumption of coagulation 
factor which results in coagulopathy [3]. Age, cluster 
of differentiation-4 (CD4) concentration, viral load, 
opportunistic infections, medications, and viral factors 
may play a role in the coagulation abnormalities 
experienced by HIV/AIDS patients. Complications due 
to these abnormalities may include cardiovascular 
disease, stroke, thromboembolism, among others, and 
may even cause an increase in HIV/AIDS mortality. 
Abnormalities in coagulation may be observed through 
changes in platelet counts, as well as changes in 
coagulation factors, both extrinsic and intrinsic [1].
Platelet plays an important role in hemostasis [3]. 
As an effector immune or inflammatory cell platelet 
releases the inflammatory mediators, interacting with 
external organisms, and increasing vascular permeability, 
and leads to hemostasis abnormality and thrombosis, 
as well as atherosclerosis. In chronic inflammation, an 
increase in platelet consumption causes an increase 
in mean platelet volume (MPV). MPV is a marker of 
platelet activation connecting the inflammation process 
to thrombosis. The higher the MPV, the more reactive 
and thrombogenic the hemostasis [4], [5]. Compared to 
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platelets with a smaller size, larger platelets have more 
granules, are more aggregative in nature, possess a 
higher concentration of thromboxane A2, and express 
more glycoprotein Ib and IIb/IIIa receptors [6]. In 
addition, platelet indices also consist of plateletcrit (PCT) 
which refers to a ratio between platelet volume and 
whole blood volume as well as platelet distribution width 
(PDW) which determines the distribution of particle size 
in platelets [7].
Previous studies have reported a deficiency of 
micronutrients in HIV/AIDS patients, including changes 
in Vitamin D concentration. Aside from maintaining 
calcium homeostasis in the human body, Vitamin D is 
also known to play a role in the natural and adaptive 
immune response [2]. Vitamin D concentration within the 
body is affected by general factors, including genetics, 
exposure to ultraviolet light, skin color, culture, seasons, 
as well as latitude [8]. Inflammation may interfere with 
renal hydroxylation, leading to a decrease in Vitamin D 
concentration [9].
HIV/AIDS infection also decreases the body’s 
immune response and the patients are prone to 
coinfections, with pulmonary TB being the most common. 
The incidence of Vitamin D deficiency increases not only 
in patients with TB but also in normal people [10], [11], [12] 
HIV-TB coinfection is also associated with Vitamin D 
deficiency [13]. The use of antituberculosis regiments 
such as isoniazid and rifampicin may interfere with 
the metabolism of Vitamin D, in addition to ARV. 
Efavirenz (EFV) and rifampicin are strong inducers of 
CYP2B6 and CYP3A enzymes, which are known to 
be associated with Vitamin D metabolism. Rifampicin 
is a more potent inducer compared to EFV in reducing 
25(OH)D concentration. Induction of CYP3A causes 
catalysis of 4-hydroxylation 25(OH)D and contributes to 
Vitamin D deficiency. In administering cotherapy of ART 
and antituberculosis, one must pay attention to potential 
drug interaction and excessive toxicity [14].
Low Vitamin D level is associated with 
an increased risk for cardiovascular diseases, 
bone diseases, infections, HIV progressivity, and 
mortality [2], [14]. Vitamin D deficiency may result in 
calcium deposition in smooth muscle cells, affecting the 
renin-angiotensin system, disturbs glucose control, and 
increases pro-inflammatory cytokines. This indirectly 
impacts hypertension and cardiac risks [6].
Vitamin D also plays a role in hemostasis. 
1,25(OH)2D influences coagulation effects through 
upregulating the expression of anticoagulant 
glycoprotein (thrombomodulin) and through 
downregulating the expression of coagulation factors 
tissue factor on monocytes. In addition, 1,25(OH)2D 
also inhibits the effect of tumor necrosing factor (TNF)-α 
which upregulates HIV RNA transcription in CD4 cells 
with latent infection [15], [16], [17].
In Vitamin D deficiency, inflammatory 
response, pro-inflammatory cytokine (TNF-α and 
interleukin-6) levels, platelet reactivity, and MPV are all 
increased [6], [18] Vitamin D is able to shift hemostasis 
toward fibrinolysis and decreases coagulation [19].
Due to varying results in previous studies on 
the relationship between Vitamin D level and hemostasis 
parameters, this study aims to compare Vitamin D level 
and coagulation abnormality in HIV/AIDS patients with and 
without pulmonary TB coinfection treated with EFV-based 
ART with and without rifampicin-based antituberculosis.
Materials and Methods
Study design
This is an analytic descriptive study with a 
cross-sectional approach conducted from August 
to October 2019 in Special Treatment Centers 
(Pusyansus) Voluntary Counseling and Testing (VCT) 
Clinic at Rumah Sakit Umum Pusat (RSUP) Haji 
Adam Malik, Medan, Indonesia. The study involved 
HIV/AIDS patients with and without pulmonary TB 
coinfection, aged ≥20 years, who were given EFV-
based ART- and rifampicin-based antituberculosis for 
<6 months. Exclusion criteria include history of Vitamin 
D supplement consumption, history of anticoagulant 
consumption, history of thromboembolism, history 
of chronic kidney disease, and history of cirrhosis, 
increased in liver function markers for more than 5 times 
normal values, and pregnancy.
Diagnosis of pulmonary TB in study subjects was 
based on clinical signs and symptoms as well as diagnostic 
work-ups such as positive sputum smear in acid-fast 
bacilli staining or positive acid-fast bacilli culture. Other 
diagnostic work-ups include GeneXpert Mycobacterium 
tuberculosis – rifampicin (MTB-RIF) or polymerase 
chain reaction as well as chest X-ray examinations with 
features suggestive of pulmonary TB. Among the many 
problems in establishing the diagnosis of pulmonary TB 
are difficulties in producing sputum for bacteriological 
examination, especially the inability to produce sputum 
with good quality and in a sufficient amount.
Data collection and procedure
The sample was collected after obtaining 
Ethical Clearance for Health Research from the Medical 
and Health Research Ethics Committee of Faculty of 
Medicine, Universitas Sumatera Utara/RSUP Haji Adam 
Malik, Medan, Indonesia [Reference No: 625/TGL/KEPK 
FK USU-RSUP HAM/2019]. Anthropometry parameters 
were measured, including weight and height, and the 
subjects were subsequently asked to complete the 
questionnaire. Data related to currently consumed ART 
and antituberculosis as well as the duration of ART were 
obtained from the medical records.
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Measurement of serum Vitamin D 25(OH)
D levels was conducted using chemiluminescent 
microparticle immunoassay ARCHITECT 25-OH Vitamin 
D. Based on US Endocrine Society Classification, levels 
of 25(OH)D were classified as Vitamin D deficiency 
(≤20 ng/mL), Vitamin D insufficiency (21-29 ng/mL), 
and Vitamin D sufficiency (≥30 ng/mL).
Complete blood count was measured with a 
hematology analyzer using flow cytometer principles. 
Results were considered normal if: Platelet count is 
between 150,000 and 450,000/µL, MPV 6.5–9.5 fL, 
PCT 0.10–0.50%, and PDW between 10.0 and 18.0%.
Prothrombin time (PT) was measured using 
semi-automatic Coatron, which recorded clotting time. 
PT was normal between 11 and 14 s and was considered 
prolonged if exceeding normal PT time by 2 s.
One subject with clinical HIV/AIDS-
pulmonary TB in the current study was found to have 
thrombocytopenia, but the measuring device was 
unable to measure MPV, PDW, and PCT; thus, the 
subject was excluded from this study.
Statistical analysis
Statistical analyses were performed using IBM 
SPSS Statistics version 25.0. Variables were described 
using proportion for categorical variables and using 
mean and standard deviation as well as the median 
and interquartile range (IQR) for numerical variables 
with normal and non-normal distribution, respectively.
Statistical significance between study groups 
was determined using χ2 and Fisher tests for categorical 
variables with normal and non-normal distribution, 
respectively, as well as non-paired t-test and Mann–
Whitney test for numerical variables with normal and 
non-normal distributions, respectively. Statistical 
significance of paired numerical variables was tested 
using paired t-test and Wilcoxon test for data with normal 
and non-normal distribution, respectively. p < 0.05 was 
considered significance.
Results
A total of 70 subjects fulfilled the inclusion 
criteria, with 33 subjects having HIV/AIDS-pulmonary 
TB treated with EFV-based ART- and rifampicin-based 
antituberculosis as well as 37 subjects with HIV/AIDS only, 
treated with EFV-based ART. There was no statistically 
significant difference in terms of mean age and gender 
between the two groups. We also observed no statistically 
significant difference in terms of the duration of EFV-
based ART between the two groups (Table 1).
Platelet index, PT, and Vitamin D levels were 
evaluated by categorizing these parameters based 
on pulmonary TB coinfection. We found a statistically 
significant difference in terms of PDW level between 
the two groups (p ≤ 0.05), while MPV (p = 0.099) and 
PCT (p = 0.625) showed no statistically significant 
difference. The level of 25(OH)D (p = 0.855) and PT 
(p = 0.206) also showed no statistically significant 
difference between the two study groups (Table 2).
Clinical characteristics, Vitamin D levels, and 
laboratory examinations categorized based on TLC levels 
on ART can be seen in Table 3. We found a statistically 
significant difference in terms of BMI (p = 0.032) and 
PDW (p = 0.050). There was no statistically significant 
difference in terms of 25(OH)D levels (p = 0.88) and PT 
(p = 0.858) between the two study groups.
Table 4 showed that most of the subjects 
treated with EFV-based ART- and rifampicin-based 
antituberculosis had deficiency Vitamin D (51.5%) 
and subjects treated with EFV-based ART only had 
insufficiency Vitamin D (48.6%). Most of the subjects 
in the two study groups had normal PT (11–15 s). We 
found that 5 of 50 subjects had prolonged PT, and 
none with shortened PT, but these were not statistically 
significant. Most of the subjects in the group treated with 
EFV-based ART- and rifampicin-based antituberculosis 
had normal platelet counts. Two subjects had high 
platelet counts, and 1 had low platelets. All subjects in 
Table 1: Demographic and clinical characteristics in the study groups
Parameters EFV-based ART + RIF-based antituberculosis (n=33) EFV-based ART (n=37) p-value
Sex, n (%)
Male 28 (84.8) 29 (78.4) 0.699
Age, median (IQR) 33 (22–52) 34 (23–68) 0.416
WHO Stage, n (%)
I/II 0 (0) 13 (35.1) 0.001
III/IV 33 (100) 24 (64.9)
BMI (kg/m2) 20.98 (2.72) 22.58 (2.87) 0.020
Duration of ART treatment (days), median (IQR) 112 (13–209) 116 (29–203) 0.702
IQR: Interquartile range, WHO: World Health Organization, BMI: Body mass index, ART: Antiretroviral therapy, EFV: Efavirenz, RIF: Rifampicin, p≤0.05 is considered statistically significant.
Table 2: Vitamin D and laboratory measurements in the study groups
Parameters EFV-based ART + RIF-based antituberculosis (n=33) EFV-based ART (n=37) p-value
TLC, median (IQR) 1669.92 (126.65–3582.26) 2080.80 (1088.51–4019.80) 0.017
Platelet (/µL), mean (SD) 313121.21 (91443.21) 296081.08 (62478.61) 0.372
MPV (fL), mean (SD) 8.86 (0.68) 9.13 (0.68) 0.099
MPV/PLT, median (IQR) 2.77×10−5 (1.70×10−5 –10.00×10−5) 3.09×10−5 (2.05×10−5–5.60×10−5) 0.202
PCT (%), mean (SD) 0.28 (0.09) 0.27 (0.05) 0.625
PDW (%), mean (SD) 8.80 (1.04) 9.38 (1.07) 0.026
25(OH)D (ng/mL), mean (SD) 22.406 (9.47) 22.78 (9.44) 0.855
PT (s), median (IQR) 12.00 (11.00–21.00) 12.20 (11.0–16.4) 0.206
IQR: Interquartile range, SD: Standard deviation, TLC: Total lymphocyte count, MPV: Mean platelet volume, MPV/PLT: Mean platelet volume/platelet count, PCT: Plateletcrit, PDW: Platelet distribution width, 25(OH)D: 
25-hydroxycholecalciferol/Calcidiol, PT: Prothrombin Time, p≤0.05 is considered statistically significant.
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the other group had normal platelet counts (p = 0.177). 
In terms of MPV, 90.9% subjects treated with EFV-
based ART- and rifampicin-based antituberculosis 
had normal platelet size, with the rest having enlarged 
platelet. In the other group, 73% subjects had normal 
platelet size and the rest 27% had enlarged platelets. 
There was no statistically significant difference in terms 
of MPV between the two groups. Most of the subjects 
in the two study groups had low PDW and we found 
no statistically significant difference. We also observed 
no statistically significant difference in terms of PCT 
between the two study groups (p > 0.05).
There was no statistically significant difference 
in terms of mean 25(OH)D levels in the two groups 
(even when broken down into Vitamin D deficiency, 
insufficiency, and sufficiency) (Table 5).
The comparison of platelet count, MPV, PCT, 
and PDW before and after treatment with EFV-based 
ART is presented in Table 6. Fifty-five subjects had 
complete records of MPV, PCT, and PDW, with 29 
subjects treated with EFV-based ART- and rifampicin-
based antituberculosis and 26 treated with EFV-based 
ART only. We observed statistically significant differences 
in terms of MPV and PDW (p ≤ 0.05) before and after 
treatment with ART. The difference of platelet count 
before and after treatment with EFV-based ART was 
statistically significant in the EFV-based ART only group 
(p = 0.021), but not in the other group. There was no 
statistically significant difference in terms of PCT in all 
study groups before and after EFV-based ART (p > 0.05).
PDW was found to be higher in subjects with 
25(OH)D level of ≥21 ng/mL in both study groups, but 
this was not statistically significant. In contrast, higher 
platelet count was found in subjects with 25(OH)D level 
of <21 ng/mL in both study groups. This was also not 
statistically significant (Table 7).
Discussion
Various things may affect Vitamin D levels 
in HIV/AIDS patients with and without pulmonary TB 
Table 3: Clinical characteristics, Vitamin D, and laboratory measurements in the study groups with TLC on ART <1200 and TLC on 
ART ≥1200
Parameters TLC on ART <1200 (n=11) TLC on ART ≥1200 (n=59) p-value
IMT (kg/m2), mean (SD) 20.12 (2.75) 22.14 (2.83) 0.032
Platelet (/µL), mean (SD) 295818.18 (111053.88) 305661.02 (70581.97) 0.700
MPV (fL), mean (SD) 8.95 (0.84) 9.01 (0.66) 0.770
MPV/PLT, median (IQR) 2.99x10-5 (1.94 x10-5-10.00x10-5) 3.09x10-5 (0.83 x10-5-1.70x10-5) 0.916
PCT (%), mean (SD) 0.26 (0.11) 0.27 (0.06) 0.780
PDW (%), mean (SD) 8.52 (1.12) 9.21 (1.05) 0.050
25(OH)D (ng/mL), mean (SD) 22.96 (8.81) 22.54 (8.4) 0.880
PT (s), median (IQR) 11.4 (11–21) 12.2 (11–16.2) 0.858
IQR: Interquartile range, SD: Standard deviation, TLC: Total lymphocyte count, MPV: Mean platelet volume, MPV/PLT: Mean platelet volume/Platelet count, PCT: Plateletcrit, PDW: Platelet distribution width, 25(OH)D: 
25-hydroxycholecalciferol/Calcidiol, PT: Prothrombin time, p≤0.05 is considered statistically significant.
Table 4: Category of Vitamin D concentration, PT, and platelet index throughout the period of ART consumption
Parameters EFV-based ART + RIF-based Antituberculosis (n=33) EFV-based ART (n=37) p-value
n % n %
25(OH)D (ng/mL)
Deficiency (≤20) 17 51.5 15 40.5 0.078
Insufficiency (21–29.9) 8 24.2 18 48.6
Sufficiency (≥30) 8 24.2 4 10.8
PT (s)
Shortened (<11) 0 0 0 0 0.555
Normal (11–15) 31 93.9 34 91.9
Prolonged (>15) 2 6.1 3 8.1
Platelet (/µL)
Low (<150,000) 1 3 0 0 0.177
Normal (150,000–450,000) 30 90.9 37 100
High (>450,000) 2 6.1 0 0
MPV (fL)
Low (<6.5) 0 0 0 0 0.106
Normal (6.5–9.5) 30 90.9 27 73
High (>9.5) 3 9.1 10 27
PDW (%)
Low (<10) 28 84.8 26 70.3 0.244
Normal (10–18) 5 15.2 11 29.7
High (>18) 0 0 0 0
PCT (%)
Low (<0.1) 1 3 0 0 0.471
Normal (0.1–0.5) 32 97 37 100
High (>0.5) 0 0 0 0
BMI: Body mass index, ART: Antiretroviral therapy, EFV: Efavirenz, RIF: Rifampicin. 25(OH)D: 25-hydroxycholecalciferol/Calcidiol, PT: Prothrombin time, MPV: Mean platelet volume, PCT: Plateletcrit, PDW: Platelet 
distribution width, p≤0.05 is considered statistically significant.
Table 5: 25(OH)D concentration and Vitamin D status
Parameters Total (n=70) EFV-based ART + RIF-based Antituberculosis (n=33) EFV-based ART (n=37) p-value
25(OH)D (ng/mL), mean (SD) 22.60 (8.40) 22.96 (8.81) 22.54 (8.4) 0.880
Vitamin D deficiency 15.53 (4.09) 15.18 (4.32) 15.92 (3.91) 0.618
Vitamin D insufficiency 25.10 (2.30) 24.01 (2.18) 25.60 (2.24) 0.108
Vitamin D sufficiency 36.05 (5.04) 36.15 (4.08) 35.85 (7.36) 0.928
ART: Antiretroviral therapy, EFV: Efavirenz, RIF: Rifampicin, 25(OH)D: 25-hydroxycholecalciferol/Calcidiol, Vitamin D deficiency: 25(OH)D ≤20 ng/mL, Vitamin D insufficiency: 25(OH)D 21-29.9 ng/mL, Vitamin D sufficiency: 
25(OH)D ≥30 ng/mL, p≤0.05 is considered statistically significant.
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coinfections. A decrease in Vitamin D levels in HIV 
infection may be attributed to pre-existing 25(OH)D 
deficiency, which contributed to the incidence of HIV. 
MTB and HIV-1 gp120 may stimulate toll-like receptors 
1/2 and induce the expression of CYP27B1 on infected 
macrophages. In addition, chronic inflammation 
in HIV infection and induction of pro-inflammatory 
cytokines such as TNF-α may cause inhibition to renal 
1α-hydroxylase, which in turn causes a decrease in 
parathyroid hormone’s (PTH) ability to convert 25(OH)
D into 1,25(OH)2D, leading to accumulation of 25(OH)
D. In addition, the complication may also play a role in 
the intensity of sunlight exposure, malnutritional, and 
decreased oral intake [20], [21]
ART also plays a role in decreased Vitamin 
D levels. EFV poses a risk for Vitamin D deficiency by 
increasing the catabolism of 25(OH)D and production 
of inactive metabolites through interaction with CYP450 
enzyme in the form of CYP24A1 induction, which converts 
25(OH)D into its inactive form, 24,25(OH)2D, as well as 
reduction of CYP2R1 transcription which inhibits the 
hydroxylation of Vitamin D3 and Vitamin D2 [20], [21], [22].
Administration of rifampicin in HIV/AIDS-TB 
coinfections, which is a strong inducer for CYP3A4, 
affects the activation of 24,25-hydroxylase Vitamin D 
which leads to the inactivation of 25(OH)D. After 2 months 
of treatment with antituberculosis, 25(OH)D level may 
increase due to improvements in the patient’s diet within 
the 1st week of antituberculosis treatment, or due to the 
decrease of inflammatory stimuli in the initial phase of 
antituberculosis treatment, leading to a decrease in 
25(OH)D hydroxylation [23].
Chronic inflammation process in HIV infection, 
which may be aggravated by pulmonary TB infection, 
and the mechanism of action of EFV-based ART, which 
may be aggravated by treatment with rifampicin-based 
antituberculosis, may work together against CYP450, 
leading to disruption in Vitamin D metabolism. Based 
on this, Vitamin D level should be lower in the group 
treated with EFV-based ART- and rifampicin-based 
antituberculosis when compared to the group treated 
with EFV-based ART only. The actual result of this study, 
however, is different. We found no significant difference 
in terms of 25(OH)D level between the group treated with 
EFV-based ART- and rifampicin-based antituberculosis 
and the group treated without rifampicin, both with 
ART duration of <6 months. Studies by Mariana and 
Rusli [24] found no difference in plasma level of EFV in 
HIV/AIDS-TB patients treated with ART for 3–6 months 
and rifampicin when compared to HIV/AIDS without 
TB. They also found that the proportion of patients with 
viral load ≥40 copy/mL was higher in the group treated 
with ART and rifampicin compared to the group without 
rifampicin, although this was not statistically significant. 
We concluded that this might contribute to the result we 
observed in terms of 25(OH)D levels between our two 
study groups.
Nylen et al. [14] reported that there was no 
significant difference in the mean plasma level of 25(OH)
D in the 4th and 16th weeks of treatment with EFV-based 
ART between HIV and HIV with TB coinfection groups. 
They also found that the effect of EFV in decreasing 
25(OH)D level was more prominent in the EFV-based 
ART only group when compared to EFV-based ART with 
rifampicin. In their study, Havers et al. [8] also stated that 
the largest proportion of decreased Vitamin D level was 
observed in the group treated with ART for 0–24 weeks 
compared to those treated for 24–48 weeks, and this 
level was significantly decreased in the group treated 
with EFV-based ART compared to the group treated 
with non-EFV-based ART. Musarurwa et al. [20], in their 
study on African subjects in Zimbabwe, reported that 
the median serum level of 25(OH)D was significantly 
higher in HIV/pulmonary TB group compared with HIV 
without pulmonary TB group.
The current study was not able to demonstrate 
changes in 25(OH)D levels before and after treatment with 
EFV-based ART, both with and without rifampicin-based 
antituberculosis, due to the unavailability of baseline data 
on pre-ART 25(OH)D levels. Gayatri et al. [13], in their 
Table 6: Comparison of platelet counts, MPV, PCT, and PDW before and after ART administration in the study groups
Parameters Total (n=55) EFV-based ART + RIF-based Antituberculosis 
(n=29)
EFV-based ART (n=26)
Baseline On ART P value Baseline On ART P value Baseline On ART P value
Platelet (/µL), mean 
(SD)
297200.00 
(114324.98)
305345.45 
(81363.66)
0.534 319344.83 
(139077.39)
312965.52 
(91261.59)
0.783 272500.00 
(73243.84)
296846.15 
(69488.82)
0.021
MPV (fL), mean (SD) 9.63 (1.10) 9.04 (0.70) <0.001 9.68 (1.26) 8.86 (0.71) 0.001 9.57 (0.93) 9.23 (0.64) 0.036
PCT (%) 0.28 (0.10) 0.28 (0.08) 0.580 0.30 (0.12) 0.28 (0.09) 0.217 0.26 (0.06) 0.27 (0.06) 0.11
PDW (%), median (IQR) 10.20 (7.00-18.00) 9.20 (7.00-11.30) <0.001 10.00 (7.00-18.00) 8.80 (7.00-11.20) <0.001 10.20 (8.00-16.00) 9.65 (7.60-11.30) 0.004
IQR: Interquartile range, SD: Standard deviation, ART: Antiretroviral therapy, EFV: Efavirenz, RIF: Rifampicin. PT: Prothrombin time, MPV: Mean platelet volume, PCT: Plateletcrit, PDW: Platelet distribution width, p≤0.05 is 
considered statistically significant.
Table 7: Relationship between Vitamin D concentration with PT and platelet index between study groups
Parameters EFV-based ART + RIF-based Antituberculosis (n=33) EFV-based ART (n=37)
25 (OH)D (ng/mL) p-value 25(OH)D (ng/mL) p-value
<21 (n=17) ≥21 (n=16) <21 (n=15) ≥21 (n=22)
Hemoglobin (g/dL), mean (SD) 12.48 (1.84) 13.23 (2.20) 0.295 13.84 (1.96) 13.83 (1.57) 0.989
PT (seconds), median (IQR) 12.20 (11.0-21.0) 11.85 (11.00-13.80) 0.561 12.00 (11.0-15.00) 12.60 (11.00-16.40) 0.088
Platelet (/µL), mean (SD) 338647.06 (90680.03) 2860000.00 (86859.27) 0.099 319200.00 (16868.46) 280318.18 (56606.74) 0.062
MPV (fL), mean (SD) 8.89 (0.69) 8.83 (0.69) 0.834 9.05 (0.77) 9.19 (0.62) 0.544
PCT (%), mean (SD) 0.30 (0.09) 0.25 (0.08) 0.112 0.29 (0.61) 0.26 (0.47) 0.086
PDW (%), mean (SD) 8.69 (0.98) 8.92 (1.11) 0.531 9.39 (1.22) 9.37 (0.98) 0.960
BMI: Body mass index, ART: Antiretroviral therapy, EFV: Efavirenz, RIF: Rifampicin. 25(OH)D: 25-hydroxycholecalciferol/Calcidiol, PT: Prothrombin time, MPV: Mean platelet volume, PCT: Plateletcrit, PDW: Platelet 
distribution width, p≤0.05 is considered statistically significant.
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study in Bali, Indonesia, also reported that serum 25(OH)
D concentration was significantly lower in the HIV-TB 
group compared to ARV-naive HIV group. They found 
that hypovitaminosis D was independently associated 
with the development of active TB in HIV patients (OR 
26.154 [90% CI: 4.371–156.541]; p < 0.001).
In the current study, there was no evidence of 
a statistically significant difference in terms of PT and 
platelet count between the two study groups. Janssen 
et al. [25] in their study stated that PT, activated partial 
thromboplastin time (APTT), and INR values were 
increased in patients with HIV-TB.
In their study, Nasir et al. [3] reported a significant 
difference in platelet count between HIV/AIDS patients 
treated with ART and ART-naive group (p = 0.001). 
They also found no significant difference in terms of PT 
(p = 0.358). In contrast, Ephraim et al. [26] reported that 
PT was significantly lower in subjects treated with ART 
compared to ART-naive (p < 0.0001) but platelet count 
was higher in the ART group (p > 0.05). The decrease 
in platelet count in HIV infection may be due to 
autoimmune destruction and thrombopoiesis disruption 
as a result of direct infection to megakaryocytes, as well 
as coagulopathy consumption in AIDS [1], [27].
When the platelet count in subjects with TLC 
<1200 was compared to those with TLC ≥1200, higher 
platelet count was observed in subjects with TLC 
≥1200; however, this was not statistically significant. 
(p = 0.70). Low CD4+ level and treatment with ART 
are risk factors for thrombocytopenia. ART causes 
bone marrow suppression, while HIV infection causes 
disruptions in thrombopoiesis [3] In their study, Raman 
et al. [1] reported no statistically significant difference 
in platelet count and PT between the groups with CD4 
<200 cell/mm3 and with CD4>200 cells/mm3 (p > 0.05). 
However, they found a statistically significant difference 
in terms of APTT (p = 0.0006).
Table 7 showed that there was no statistically 
significant difference in terms of PT and platelet index 
between subjects with 25(OH)D levels of <21 ng/mL 
and ≥21 ng/mL. Coşkun and Şahin [7], in their study on 
children aged 0–18 years, reported that there was no 
correlation between 25(OH)D level and platelet index. 
Elbers et al. [28] stated that there were no changes in 
PT after 2 months of supplementation with Vitamin D 
in patients with Vitamin D deficiency and secondary 
hyperparathyroidism. Korzonek-Szlacheta et al. [18], in 
their study on patients with stable coronary artery disease, 
found that MPV value was highest in the group with 
Vitamin D deficiency (25(OH)D <10 ng/mL) and lowest in 
the Vitamin D insufficiency group (25(OH)D 20–30 ng/mL) 
(p < 0.001). PDW was highest in the Vitamin D deficiency 
and moderate Vitamin D deficiency groups.
The current study has several limitations. 
We were not able to determine whether the patients’ 
Vitamin D deficiency was chronic due to unavailability of 
baseline data, lack of baseline CD4 data, and due to the 
fact that we did not assess factors which are commonly 
associated with Vitamin D levels such as skin color, food 
sources, and lifestyle. In addition, most of our subjects 
were below 40 years old. Further studies with a larger 
sample size were required to determine the difference 
of Vitamin D level and hemostasis parameters in the 
two study groups.
Conclusion
We found no relationship between 25(OH)
D concentration and PT or platelet index in HIV/AIDS 
patients with and without pulmonary TB treated with 
EFV-based ART- and rifampicin-based antituberculosis 
for <6 months.
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